<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23700449</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>5</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection.</ArticleTitle><Pagination><StartPage>e64024</StartPage><MedlinePgn>e64024</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e64024</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0064024</ELocationID><Abstract><AbstractText>The emerging human enterovirus 71 (EV71) represents a growing threat to public health, and no vaccine or specific antiviral is currently available. Human intravenous immunoglobulin (IVIG) is clinical used in treating severe EV71 infections. However, the discovery of antibody dependent enhancement (ADE) of EV71 infection illustrates the complex roles of antibody in controlling EV71 infection. In this study, to identify the distinct role of each IgG subclass on neutralization and enhancement of EV71 infection, different lots of pharmaceutical IVIG preparations manufactured from Chinese donors were used for IgG subclass fractionation by pH gradient elution with the protein A-conjugated affinity column. The neutralization and ADE capacities on EV71 infection of each purified IgG subclass were then assayed, respectively. The neutralizing activity of human IVIG is mainly mediated by IgG1 subclass and to less extent by IgG2 subclass. Interestingly, IgG3 fraction did not have neutralizing activity but enhanced EV71 infection in vitro. These results revealed the different roles of human IgG subclasses on EV71 infection, which is of critical importance for the rational design of immunotherapy and vaccines against severe EV71 diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Rui-Yuan</ForeName><Initials>RY</Initials><AffiliationInfo><Affiliation>Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Da-Yong</ForeName><Initials>DY</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Rui-Ju</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Jian-Feng</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guang-Chuan</ForeName><Initials>GC</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao-Feng</ForeName><Initials>XF</Initials></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yong-Qiang</ForeName><Initials>YQ</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Shun-Ya</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiao-Yu</ForeName><Initials>XY</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Fang</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Fu-Jun</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>E-De</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Cheng-Feng</ForeName><Initials>CF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>Commercial IVIG products are kindly provided by Tonrol and Ronsen Pharmaceuticals, and this does not alter the authors&#x2019; adherence to all the PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23700449</ArticleId><ArticleId IdType="pmc">PMC3659118</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0064024</ArticleId><ArticleId IdType="pii">PONE-D-13-04141</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McMinn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26: 91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129: 304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10: 778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Huang X, Zhu S, Chen H, Yu Q, et al. (2011) The persistent circulation of enterovirus 71 in People&#x2019;s Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 6: e25662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, Li J, Xiao Y, et al. (2009) Enterovirus 71 outbreak in the People&#x2019;s Republic of China in 2008. J Clin Microbiol 47: 2351&#x2013;2352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Chang KC, Kao CM, Chang SP, Tung YY, et al. (2009) Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. J Virol 83: 6477&#x2013;6483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698549</ArticleId><ArticleId IdType="pubmed">19386699</ArticleId></ArticleIdList></Reference><Reference><Citation>Abzug MJ, Keyserling HL, Lee ML, Levin MJ, Rotbart HA (1995) Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis 20: 1201&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pubmed">7620000</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, et al. (2006) Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol 12: 921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066158</ArticleId><ArticleId IdType="pubmed">16521221</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9: 1299&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, et al. (2000) Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7: 523&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Chen IC, Su LY, Huang KJ, Lei HY, et al. (2010) Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin Vaccine Immunol 17: 1517&#x2013;1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953001</ArticleId><ArticleId IdType="pubmed">20685937</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Cao RY, Deng YQ, Tian X, Jiang T, et al. (2011) Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J 8: 106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060144</ArticleId><ArticleId IdType="pubmed">21385398</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehlhop E, Ansarah-Sobrinho C, Johnson S, Engle M, Fremont DH, et al. (2007) Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2: 417&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2194657</ArticleId><ArticleId IdType="pubmed">18078693</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmeister Y, Planitzer CB, Farcet MR, Teschner W, Butterweck HA, et al. (2010) Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus. J Virol 85: 1896&#x2013;1899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3028917</ArticleId><ArticleId IdType="pubmed">21123389</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigo WW, Block OK, Lane C, Sukupolvi-Petty S, Goncalvez AP, et al. (2009) Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology 394: 175&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783259</ArticleId><ArticleId IdType="pubmed">19833371</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV (2004) Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci 25: 306&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127229</ArticleId><ArticleId IdType="pubmed">15165745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao R, Han J, Deng Y, Yu M, Qin E, et al. (2010) Presence of high-titer neutralizing antibodies against enterovirus 71 in intravenous immunoglobulin manufactured from Chinese donors. Clin Infect Dis 50: 125&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">20001529</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo ST, Chiang PS, Chao AS, Liou GY, Lin R, et al. (2009) Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis 15: 581&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671432</ArticleId><ArticleId IdType="pubmed">19331737</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabenau HF, Richter M, Doerr HW (2010) Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol 199: 45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">19941005</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao RY, Han JF, Jiang T, Tian X, Yu M, et al. (2011) In vitro and in vivo characterization of a new enterovirus type 71-specific human intravenous immunoglobulin manufactured from selected plasma donors. J Clin Virol 51: 246&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">21641277</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Cao RY, Tian X, Yu M, Qin ED, Qin CF (2010) Producing infectious enterovirus type 71 in a rapid strategy. Virology J 7: 116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892457</ArticleId><ArticleId IdType="pubmed">20525351</ArticleId></ArticleIdList></Reference><Reference><Citation>Duhamel RC, Schur PH, Brendel K, Meezan E (1979) pH gradient elution of human IgG1, IgG2 and IgG4 from protein A-sepharose. J Immunol Methods 31: 211&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">42659</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharf O, Golding H, King LR, Eller N, Frazier D, et al. (2001) Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. J Virol 75: 6558&#x2013;6565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114379</ArticleId><ArticleId IdType="pubmed">11413323</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. American Journal of Epidemiology 27: 493&#x2013;497.</Citation></Reference><Reference><Citation>Wang SM, Lei HY, Huang MC, Su LY, Lin HC, et al. (2006) Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol 37: 47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16861032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Liu CC (2009) Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther 7: 735&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">19681701</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 29: 4362&#x2013;4372.</Citation><ArticleIdList><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Jelley-Gibbs DM, Plitnick LM, Gosselin EJ (1999) Differences in IgG subclass do not effect immune complex-enhanced T cell activation despite differential binding to antigen presenting cells. Hum Immunol 60: 469&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408796</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori S, Takeuchi T, Kanda T (2008) Antibody-dependent enhancement of adeno-associated virus infection of human monocytic cell lines. Virology 375: 141&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295295</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Stollar V, Lin JY, Chang SC, Chen GW, et al. (2004) Identification of genes involved in the host response to enterovirus 71 infection. J Neurovirol 10: 293&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15385252</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer KC, Lal AA, Mirel LB, Otieno J, Ayisi J, et al. (2004) Polymorphism of Fc receptor IIa for immunoglobulin G is associated with placental malaria in HIV-1-positive women in western Kenya. J Infect Dis 190: 1192&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319871</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, et al. (2009) Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15: 794&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, et al. (2009) Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15: 798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauter P, Lobert PE, Lucas B, Varela-Calvino R, Alm G, et al. (2007) Role of the capsid protein VP4 in the plasma-dependent enhancement of the Coxsackievirus B4E2-infection of human peripheral blood cells. Virus Res 125: 183&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">17291618</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD (2009) Vaccine-induced enhancement of viral infections. Vaccine 27: 505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7131326</ArticleId><ArticleId IdType="pubmed">19022319</ArticleId></ArticleIdList></Reference><Reference><Citation>Hocart MJ, Mackenzie JS, Stewart GA (1990) Serum IgG subclass responses of humans to inactivated and live influenza A vaccines compared to natural infections with influenza A. J Med Virol. 30: 92&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">2313275</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>